Company Description
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections.
In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders.
Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers.
The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2002 |
| IPO Date | May 28, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,500 |
| CEO | Yvonne Greenstreet |
Contact Details
Address: 675 West Kendall Street, Henri A. Termeer Square Cambridge, Massachusetts 02142 United States | |
| Phone | 617 551 8200 |
| Website | alnylam.com |
Stock Details
| Ticker Symbol | ALNY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178670 |
| CUSIP Number | 02043Q107 |
| ISIN Number | US02043Q1076 |
| Employer ID | 77-0602661 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yvonne L. Greenstreet M.B.A., M.D. | Chief Executive Officer and Director |
| Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board |
| Jeffrey V. Poulton M.B.A. | Chief Financial Officer and Executive Vice President |
| Bryan Andrew Supran J.D. | Chief Legal Officer |
| Dr. Pushkal P. Garg M.D. | Executive Vice President and Chief Research & Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | Filing |
| Nov 13, 2026 | SCHEDULE 13G/A | Filing |
| Nov 5, 2026 | SCHEDULE 13G/A | Filing |
| Nov 5, 2026 | 8-K | Current Report |
| Oct 30, 2026 | SCHEDULE 13G | Filing |
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 2, 2026 | 144 | Filing |
| Jul 30, 2026 | 10-Q | Quarterly Report |
| Jul 30, 2026 | 8-K | Current Report |